Page header

Recommendation of the President – Calcort (deflazacort)

On 11 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 142/2024 on the appraisal on the appropriateness of issuing approvals for the reimbursement of the medicinal product Calcort (deflazacort) for the indication Duchenne muscular dystrophy

 

Publication in Public Information Bulletin (BIP) >>